Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) is projected to announce its earnings results after the market closes on Monday, February 24th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Day One Biopharmaceuticals Price Performance
NASDAQ:DAWN traded up $0.45 during trading hours on Thursday, reaching $12.23. 821,476 shares of the company were exchanged, compared to its average volume of 988,142. The business has a 50 day moving average of $12.39 and a 200 day moving average of $13.48. Day One Biopharmaceuticals has a 1-year low of $11.13 and a 1-year high of $18.07. The company has a market capitalization of $1.23 billion, a P/E ratio of -11.87 and a beta of -1.46.
Analyst Ratings Changes
Several research firms have recently issued reports on DAWN. The Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, February 10th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. TD Cowen raised shares of Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. Bank of America cut their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $35.71.
Get Our Latest Report on DAWN
Insider Transactions at Day One Biopharmaceuticals
In related news, insider Samuel C. Blackman sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the transaction, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. This represents a 2.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.40% of the company's stock.
Day One Biopharmaceuticals Company Profile
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
See Also
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
